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In Brief
Abnormal Wnt pathway activation is involved in the initiation of most colorectal cancers; however, little is known about its contribution to metastatic outgrowth. Ragusa et al. report that the Wnt target transcription factor PROX1 is produced in a subpopulation of colon cancer stem/progenitor cells and orchestrates the transcriptional network responsible for autophagy-dependent survival of metastases. Inactivation of PROX1 or PROX1-associated pathways prevents expansion of macrometastases and may provide new targets for therapeutic intervention in Wnt high colorectal cancer.
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INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancerrelated mortality. The prognosis is especially poor for metastatic CRC, with overall 5-year survival rates of 5%-8% (Cunningham et al., 2010) . Current treatment options include resection of solitary metastases and combinations of anti-vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) inhibitors and cytotoxic therapy. However, these targeted therapies are effective only in a small subset of patients with metastatic disease and treatment benefits are short-lived, further highlighting the need for a better understanding of metastatic CRC (De Roock et al., 2011) . Wnt signaling is essential for the maintenance of normal intestinal stem cells and is aberrantly activated in a significant proportion of CRCs (Clevers, 2013) . The evolutionary conserved transcription factor PROX1 is a Wnt target gene in colon adenomas, where it contributes to the transition from early to dysplastic stage (Petrova et al., 2008) . Prox1 is not expressed in normal intestinal stem cells, demonstrating that only oncogenic Wnt signaling triggers Prox1 expression (Petrova et al., 2008) . Increased epithelial-to-mesenchymal transition (EMT) was recently reported in PROX1-expressing CRC cells in vitro (Lu et al., 2012) . However, the role of PROX1 in metastatic CRC has not been investigated. Here, we report that PROX1 is expressed in stem-like cells in a subset of Wnt high colon carcinomas and metastases. PROX1 acts as a key regulator of macrometastatic lesions outgrowth by promoting adaptation of tumor cells to hypoxia and nutrient deprivation. Furthermore, we show that targeting autophagy efficiently eliminates the growth advantage of PROX1 + cells. We identify direct PROX1 target genes in CRC cells and show that a pro-apoptotic member of BCL2 family, BCL2L15, is one of the downstream effectors of PROX1. Our data thus identify a cancer-specific component of the Wnt signaling required for outgrowth of metastases and suggest that inhibition of PROX1, or PROX1-regulated pathways, might constitute a new therapeutic approach.
RESULTS
PROX1 Is Expressed in Progenitor/Stem Cells in Wnt high
Colon Cancer Metastases
We examined whether PROX1 expression correlates with Wnt signaling, stem-like/progenitor markers, cell differentiation, and proliferation, using transcriptomes of 166 primary CRCs and 20 lung metastases (Sheffer et al., 2009 ). PROX1 expression significantly correlated with stem/progenitor cell markers and Wnt targets LGR5, ASCL2, RNF43, and EPHB2 (Clevers, 2013) in primary tumors, and this correlation was further significantly increased in lung metastases ( Figure 1A ; p < 0.05). In contrast, PROX1 expression in metastases anticorrelated with the differentiation marker KRT20 ( Figure 1A) . Analysis of the proliferation signature MKI67, FOXM1, MYC, and AURKB revealed that PROX1 levels did not correlate with the signature in primary tumors, whereas PROX1 low metastases had a lower proliferation index ( Figure 1B ). We next asked how PROX1 expression correlates with molecular subtypes of CRC described by Budinska et al. (2013) and Sadanandam et al. (2013) . Highest PROX1 levels were found in Wnt high subtypes in both classification schemes (Figures S1A and S1B) . In contrast, PROX1 was low in more-differentiated subtypes, such as the subtype A with high expression of differentiation markers and subtype C with high frequency of cancer-specific DNA hypermethylation (CIMP-H) of the Budinska et al. classification. Most of CIMP CRCs are also mismatch repair (MMR) deficient due to hypermethylation of the MLH1 gene promoter (Truninger et al., 2005) . In agreement with these results, PROX1 was low in MMR-deficient CRCs (Figures S1C-S1E). We further confirmed these data using the Pan-European Trials in Alimentary Tract Cancers database, containing microsatellite instability status analysis for 688 CRC primary colon carcinomas (Roth et al., 2010 ; Figure S1F ). The bioinformatics analysis predicted that PROX1 correlates with stem/progenitor markers, high Wnt signaling, and proliferation and anticorrelates with differentiation markers. Interrogation of transcriptomes from human CRC stem cells, stratified by the levels of Wnt signaling (de Sousa E Melo et al., 2011) , demonstrated that PROX1 was significantly higher in Wnt high versus Wnt low cancer stem cells ( Figure 1C ; p = 9.7 3 10 À4 ). To evaluate PROX1 protein levels in metastasis versus primary tumor, we stained 33 matched primary CRCs and their metastases. Lung and lymph node metastases had significantly higher levels of PROX1 in comparison to the primary tumors, with a positive trend for other metastatic sites ( Figures 1D, 1E , and S1G). To establish whether PROX1 is expressed in stem/progenitor cells, we analyzed coexpression of PROX1 and EPHB2, CD44 and BMI1, previously shown to encompass progenitor/stem cell populations (Todaro et al., 2014; Martorell et al., 2014; MerlosSuá rez et al., 2011; Kreso et al., 2014) . We also analyzed b-catenin nuclear/cytoplasmic localization as a marker of Wnt pathway activation, proliferation, and differentiation. In agreement with the bioinformatics analyses, differentiated KRT20 + cells did not express PROX1 and, in metastases, cell proliferation correlated with levels of PROX1 (Figures 1F and S1H-S1J). The majority of PROX1 + cells also coexpressed EPHB2 and BMI1, 50% had nuclear/cytoplasmic b-catenin, and 17% coexpressed CD44 or proliferation markers. A significant proportion of EPHB2 + , BMI1 + , CD44 + , and PH3 + cells did not express PROX1 ( Figures 1G-1I ). Thus, in human metastases, PROX1 partially colocalizes with markers of stem/progenitor cells, proliferation, and activated WNT signaling.
To extend our observations to a model with a well-characterized stem cell compartment, we analyzed adenomas from Apc fl/fl ;Lgr5-EGFP-Ires-CreERT2 mice. GFP marks Lgr5 + normal and transformed stem cells, which give rise to differentiated progeny in both normal intestine and adenoma (Schepers et al., 2012 S1N ). We next tested whether Prox1 is necessary to sustain growth of AKP organoids in a colony-forming assay, where a single stem cell gives rise to a 3D ''organoid'' structure . Downregulation of Prox1 significantly decreased the number of colonies formed by single AKP cells, thus demonstrating that Prox1 maintains clonogenic growth ( Figures 1K and 1L ). Expression of progenitor/stem cell markers and Wnt target genes Lgr5, Ascl2, Rnf43, and EphB2 was not modified in early organoids at day 5, despite downregulation of Prox1 ( Figure 1M ). However, their expression was lower in organoids by day 15 ( Figure 1N ). Taken together with our previous data showing that Prox1 does not affect general Wnt reporter activity (Petrova et al., 2008) , these results indicate that Prox1 does not directly regulate stem/progenitor gene expression or general Wnt signaling, but it rather maintains the clonogenic capacity of CSCs.
PROX1 Controls CRC Metastasis
Analyses of human tumor samples indicated that PROX1 expression is elevated in a subset of metastases ( Figure 1E ), consistent with potential involvement of PROX1 in metastatic CRC. To clarify this, we used an orthotopic model, in which CRC cells form metastases in lymph nodes, liver, and lungs after intracecal injection (Cé spedes et al., 2007) . To study if PROX1 is sufficient to promote metastasis, we overexpressed PROX1 and its inactive form PROX1mut, bearing mutations in the DNA-binding domain, in PROX1-negative DLD1 CRC cells. As another control, we used cells transfected with an empty vector (Figure 2A) . The primary tumor size was similar between the groups, and there was no difference in primary tumor weights (Figures 2B and 2C) . However, significantly more DLD1-PROX1 cells were present in lungs, liver, and lymph nodes ( Figure 2B ). Metastatic incidence was increased only in lymph nodes of PROX1 group ( Figure 2D ). In all tissues, PROX1 + metastases were 2-to 5-fold larger than the control lesions ( Figures 2E-2G ). PROX1 + metastases displayed higher levels of proliferation marker phosphohistone H3. Strikingly, proliferating cells were observed throughout the lesion in DLD1-PROX1 metastases, whereas in the control, metastases proliferation was restricted to the outer rim as a result of massive central necrosis ( Figure 2H ). We next asked whether PROX1 depletion in PROX1 + SW620
cells affects development of metastases ( Figures S2A-S2C ). Depletion of PROX1 did not affect growth of primary tumors; however, we observed marked differences in the development of metastases ( Figures S2D-S2F ). In this case, there were more PROX1 + metastases, which were also bigger in comparison to the controls ( Figures S2E and S2F ). Depletion of PROX1 reduced metastases proliferation and induced extensive necrosis and apoptosis, whereas little cell death was observed in primary tumors (Figures S2G and S2H) .
To confirm that these phenotypes were not the result of longterm cell selection, we studied SW480R/PROX1si cells, in which PROX1 is suppressed upon administration of doxycycline (Petrova et al., 2008;  Figure S2I ). Depletion of PROX1 reduced metastases size and incidence without affecting the primary tumor (Figures S2J and S2K) . Doxycycline treatment had no effect on SW480R/GFPsi metastases, in which a control small hairpin RNA (shRNA) was induced (Figures S2J and S2L) . Similar to other models, suppression of PROX1 resulted in formation of large central necrotic areas ( Figure S2M ). In summary, lossand gain-of-function experiments show that PROX1 is necessary and sufficient to promote CRC metastases.
PROX1 Fuels Metastases Outgrowth
Metastasis requires several steps: invasion, extravasation, survival in the circulation, colonization of distal organs, and outgrowth of macrometastases (Chaffer and Weinberg, 2011) . PROX1 promoted EMT in vitro by suppressing E-cadherin (Lu et al., 2012) . However, in our hands, PROX1
À and PROX1 + cells expressed comparable levels of E-cadherin and EMT marker vimentin ( Figures 3A and S3A ). PROX1 did not increase invasion in in vitro assays or local invasion in primary tumors, and vascular density was comparable in PROX1 + versus PROX1 À tumors . Thus, enhanced local invasion and angiogenesis are not major contributing factors in our models.
To test the role of PROX1 during the subsequent steps of metastasis, we injected enhanced GFP (EGFP)-tagged SW620 In tumor spheroids, diffusion of nutrients and oxygen is decreased in the center, resulting in a hypoxic/low-nutrient environment and cell death (Hirschhaeuser et al., 2010 Figures 5C-5F ). In contrast, hypoxic DLD1-PROX1 cells had somewhat enhanced proliferation and low cell death ( Figures 5D, 5F , and 5G). PROX1 + cells were also more resistant to cell growth arrest and cell death elicited by the low glucose or glutamine, but not by etoposide, which induces apoptosis through DNA damage ( Figures 5D,  5F , 5G, and S5A). Similar results were observed in another cell line SW620 (Figures S5A-S5D ). These data indicate that PROX1 sustains cell survival and proliferation under metabolic stress.
PROX1 Promotes Metabolic Adaptation
Increased glycolysis is one of the key characteristics of cancer cells. However, cancer cells can also use oxidative phosphorylation rather than glycolysis to sustain growth (e.g., Haq et al., 2013; Janiszewska et al., 2012 and 5G). In the absence of glutamine, PROX1 + cells, unlike the control cells, sustained both OCR and ECAR and increased glycolysis after treatment with the mitochondrial oxidative phosphorylation inhibitor trifluorocarbonylcyanide phenylhydrazone ( Figures S5E and S5F ). Better adaptation to glucose or glutamine starvation and oxidative phosphorylation inhibition was also observed in PROX1 + SW620 cells (data not shown). In order to evaluate cell metabolism in hypoxia, we measured ECAR and OCR in cells cultured for 24 hr in 0.1% O 2 . SW620 PROX1 + cells had higher basal level of oxidative phosphorylation in normoxia and also displayed a higher glycolysis rate in response to hypoxia ( Figures S5G and S5H) . Similarly, DLD1-PROX1 cells cultured in hypoxia and low glutamine displayed higher levels of glycolysis in comparison to the control cells (data not shown). Taken together, these data indicate that, whereas not favoring either oxidative phosphorylation or glycolysis, PROX1 promotes cell adaption to changes in fuel source. Such metabolic fitness of PROX1 + cells would confer growth advantages under unfavorable conditions that tumor cells encounter during metastasis outgrowth.
Continuous PROX1 Expression Is Necessary for Growth CRC Metastases
To evaluate the therapeutic potential of targeting PROX1, we studied whether ablation of PROX1 affects established metastases. SW480R/PROX1si cells, expressing a PROX1-targeting shRNA under the control of doxycycline, were injected intracecally. Doxycycline treatment was initiated 30 days later, when both primary and metastatic lesions already developed. PROX1 depletion did not affect primary tumors, despite downregulation of PROX1 protein ( Figures 6A, 6B , and S6A). However, further growth of metastases was arrested in the absence of PROX1, whereas they continued to grow in the control mice (Figures 6A , 6C, S6B, and S6C). Thus, PROX1 inhibition may be a (legend continued on next page) useful therapeutic option for treatment of PROX1 + CRC metastases. Targets  Metastatic PROX1 + Cells
Pharmacological Inhibition of Autophagy
With few exceptions, therapeutic targeting of transcription factors is difficult (Koehler, 2010) . Therefore, we sought to identify pharmacological approaches for targeting PROX1 + CRC cells. One of the pathways that mediate stress-induced metabolic adaptation is autophagy, a process of recycling cell components to maintain nutrient flux and energy homeostasis (White, 2012) . To test whether autophagy underlies PROX1-induced survival under metabolic stress, we treated cells with chloroquine (CQ), which inhibits autophagy by preventing endosomal acidification. CQ-treated PROX1 + and PROX1 À cells accumulated enlarged LC3B + autophagosomes in hypoxia, demonstrating efficient autophagy inhibition ( Figure S6D ). CQ prevented proliferation of hypoxic PROX1 + cells, whereas it had little effect on PROX1 + or PROX1 À cells under normoxic conditions ( Figures   6D, 6E , and S5E). We also treated cells with another autophagy inhibitor, 3-methyl adenine (3-MA) (White, 2012) . Similar to the CQ, 3-MA induced cell death of PROX1 + cells under hypoxic conditions ( Figure S6F ). Thus, autophagy inhibition and metabolic stress induce a synthetically lethal phenotype in PROX1 + cells. It also suggests that autophagy inhibition, which is now under clinical trials in metastatic CRC (http://clinicaltrials.gov/ show/NCT01006369), may preferentially target PROX1 + tumor cells.
To evaluate this hypothesis, we injected mice intravenously with PROX1 + or PROX1 À SW620 cells and monitored the effects of CQ on liver metastases. CQ was administered either at high (40 mg/kg; Sasaki et al., 2012) or at low (10 mg/kg) dosage, which better mimics the situation in patients (Kimura et al., 2013) . The high-CQ regimen significantly reduced the size, but not the number, of liver metastases ( Figures S6G and S6H) . Strikingly, these macrometastases had increased necrosis, with frequently only a rim of live cells ( Figures S6I and S6J ). PROX1 À cells did not form liver macrometastases at this time point, and CQ had no further effect on cell death ( Figures S6G-S6I ). Importantly, although low-CQ regimen did not reduce liver macrometastasis incidence or size ( Figures 6F and S6K) , it still strongly induced tumor necrosis and decreased cell proliferation ( Figures 6G, 6H , S6L, and S6M). Decreased angiogenesis can also lead to tumor necrosis. Therefore, we quantified tumor vessel density. Vascular density was comparable in treated versus control metastases ( Figures  6H and S6N ), arguing that CQ acts directly on tumor cells. Proliferating cells in CQ-treated tumors were found only at the tumorstroma interface, characterized by abundant vasculature, showing that treated cells need oxygen-and nutrient-replete conditions to proliferate ( Figures 6H, S6L, and S6N ). Intriguingly, PROX1 had little effect on orthotopically implanted primary tumors, whereas it promoted growth of metastases (Figures 2, 6A-6C , and S2). To explain this differential response, we analyzed proliferation and apoptosis in metastases versus primary tumors. In two different models, PROX1 + and PROX1
À primary tumors proliferated at low and comparable rates and had low levels apoptosis ( Figures 6I, 6J , and S6O; data not shown). In contrast, proliferation was high in PROX1 + metastases, whereas apoptosis was induced in PROX1 À metastases ( Figures 6J and S6O ). Because only PROX1 + cells can productively use autophagy ( Figure 6D ), we compared responses to autophagy inhibition of primary tumors and metastases. Treatment with CQ did not affect primary tumor proliferation ( Figures  6K, 6L , and S6P) or metastasis incidence ( Figure S6Q ). However, CQ significantly suppressed proliferation of PROX1 + metastases ( Figures 6K and 6L ). Furthermore, although CQ treatment did induce some necrosis in primary tumors, necrosis levels were significantly higher in PROX1 + metastases ( Figure 6M ). Importantly, the treatment had no effect on vascular density ( Figure S6R ).
To better understand why PROX1 + metastases respond better than primary tumors to autophagy inhibition, we next compared autophagy in primary versus metastatic lesions by quantifying differences in LC3B levels between the control and CQ-treated lesions. Such autophagic flux is a more accurate measure of autophagy than the steady-state level of processed LC3B (Mizushima et al., 2010) . Autophagic flux was higher in metastases, regardless of the levels of PROX1 (Figures 6N-6Q ). Our data thus show that CQ efficiently targets PROX1 + cells in macrometastases. They also indicate that the metastatic CRC cells have higher levels of autophagy, which points to increased metabolic stress in the sites of metastases. Although the mechanisms remain to be elucidated, these results show that PROX1 + metastases may respond to autophagy inhibition in patients.
BCL2L15 Is a Direct Target of PROX1, which Suppresses Tumor Growth
To study the transcriptional network regulated by PROX1, we carried out chromatin immunoprecipitation sequencing (ChIPseq) and transcriptome analysis after small interfering RNA (siRNA)-mediated knockdown of PROX1 in SW480R cells (Figure S7A) . The analyses identified 23,450 PROX1-binding sites (false discovery rate [FDR] < 0.001) and 444 PROX1-dependent genes (FDR < 0.05 and fold change [FC] > 1.5). To find how PROX1 DNA binding correlates with changes in gene expression, we mapped these genes to nearby ChIP-seq-binding regions. Unaffected genes (mean expression value >8 and FC < 1.5) were used as reference. We observed that PROX1 preferentially binds in the vicinity of genes induced by PROX1 depletion ( Figure S7B ). Thus, as found in other cell types (e.g., Steffensen et al., 2004) , PROX1 acts as a transcriptional repressor. presented as mean ± SEM. Two-way ANOVA; *p < 0.05; **p < 0.005; ***p < 0.001; red *, PROX1 versus control in indicated condition; black *, significant change of the same cell type in different conditions.
As PROX1 promoted survival of both DLD1 and SW480R cells, we reasoned that important direct targets should be repressed in both cell lines. To identify such targets, we combined ChIP-seq data with gene expression profiling results in two cell types. We identified 40 genes, repressed by PROX1 and carrying PROX1-binding sites (FDR < 0.05; Tables S1, S2, and S3), out of which seven genes (ABAT, BCL2L15, CAV1, IQGAP2, SEMA3C , SLC7A7, and TNFRSF9) were repressed by PROX1 more than 2-fold ( Figures 7A, S7C, and S7D ). For most of these genes, the direct connection to CRC progression remains to be investigated. However, BCL2 family member, BCL2L15, acts as a conditional pro-apoptotic gene in CRC cells in vitro (Dempsey et al., 2005) and Cav1 À/À mice have more aggressive lesions in a genetic model of intestinal cancer (Friedrich et al., 2013 Figure 7D ). We overexpressed BCL2L15, CAV1, or another PROX1 target TNFRSF9 in PROX1 + CRC cells ( Figure S7E ) and tested growth and survival of these cells under normoxia and hypoxia. BCL2L15 and, to a lesser extent, CAV1 reduced proliferation and increased apoptosis of PROX1 + cells under hypoxia ( Figures   7E, 7F , and S7F). In contrast, overexpression of TNFRSF9 had no effect ( Figure S7F ). Furthermore, BCL2L15 overexpression in PROX1 + CRC cells drastically reduced the number and size of metastases after intravenous (i.v.) injections (Figures 7G-7J ).
To test the effects of BCL2L15 inactivation, we used the AKP intestinal organoid model, in which Bcl2l15 is expressed in Prox1-negative cells and is further induced after Prox1 depletion ( Figures S7G and S7H ). We found that Bcl2l15 depletion enhanced clonogenic growth of intestinal organoids in vitro (Figures 7K and S7I) , as well as proliferation and growth of organoidderived tumors in vivo ( Figures 7L-7N and S7J ), without affecting cell survival ( Figure 7O ). As expected, Prox1 depletion reduced colony formation and tumor growth under the same conditions ( Figures 7K-7O, S7I, and S7J ).
To further analyze the significance of BCL2L15 and CAV1 regulation by PROX1 in human CRC in vivo, we studied BCL2L15 and CAV1 protein localization in human CRC. BCL2L15 and PROX1 displayed a mutually exclusive localization pattern both in metastases and primary tumors (Figures 7P and  S7K ; data not shown). In contrast, CAV1 was generally low in CRC cells independently of PROX1 status (data not shown). These results suggest that BCL2L15 suppression is a more-specific marker for PROX1 activity. Moreover, luciferase reporter assays showed that PROX1 directly repressed the activity of the 3 0 PROX1-binding region in the BCL2L15 locus ( Figures S7L and  S7M ). BCL2L15 mRNA levels were also strongly reduced in CRC tumors (n = 230; p = 2.11 3 10 À8 ; Figure 7Q ) and showed a significant negative correlation with PROX1 ( Figure 7Q ; p = 1.8 3 10 À4 ). In summary, our genome-wide analyses identified a number of potential direct PROX1 targets in CRC (Table S1) , whose roles still need to be investigated. Here, we show that BCL2L15 is an important, even if likely not the only, effector of PROX1 in CRC, whose suppression in part recapitulates the effects of PROX1.
DISCUSSION
We report that the colon-cancer-specific Wnt target PROX1 is highly expressed in colon cancer metastases, where it is present in a subset of cancer stem/progenitor cells. We also show that, in advanced CRC, PROX1 sustains growth of macrometastases through the evasion of apoptosis and metabolic adaptation. Previous studies investigated the mechanisms of local invasion in primary CRC tumors. They established important roles for Wnt and Notch signaling, EMT, and the tumor-stroma interactions (e.g., Dolznig et al., 2011; Sonoshita et al., 2011; Spaderna et al., 2008; Wolf et al., 2012) . However, mechanisms governing outgrowth of metastases are not well understood. Yet metastatic CRC is a major clinical challenge, with limited patient survival and few therapeutic options available, especially for patients with activating KRAS mutations, which confer resistance to anti-EGFR therapy (Cunningham et al., 2010; Van Emburgh et al., 2014) . In this study, we investigated the role of the transcription factor PROX1 in the development of CRC metastases. Expression of PROX1 in primary CRC tumors is not an independent prognostic factor (Skog et al., 2011) . However, we found that PROX1 levels are generally increased in metastases and a proportion of PROX1 À primary tumors give rise to PROX1 + metastases. Large expression data sets from metastatic lesions will clarify whether high levels of expression of PROX1 in a metastasis correlates with survival after relapse. Nevertheless, already now our data suggest that, in advanced CRC, PROX1 may be important in the context of metastatic disease. Analysis of PROX1 expression patterns in human metastases and mouse models demonstrated that PROX1 is expressed only upon transformation and it may delineate a distinct subpopulation of cancer stem/progenitor cells. Furthermore, in vitro analyses of the intestinal organoid model demonstrated that, while Prox1 does not directly control the expression of stem/progenitor-associated genes or general Wnt pathway activity, it is essential to maintain clonogenic growth. Our data are in agreement with the results of Wiener et al., who show that Prox1 is essential for the expansion of the stem cell pool in transformed but not in normal intestinal stem cells (Wiener et al., 2014) . Through the analysis of mouse models of CRC metastasis, we found that PROX1 is dispensable for growth of primary tumors, cell survival in the bloodstream, or extravasation; however, it promotes outgrowth of metastases. At least in part, this property of PROX1 relies on its ability to override cell death imposed by metabolic stress, such as hypoxia or low-nutrient environment. Taken together, our data suggest that, in CRC metastases, there exists a subpopulation of PROX1 + stem/progenitor cells, which are highly resistant to metabolic insults and can thus fuel metastatic growth. These data identify PROX1 as an important player in CRC stem/progenitor cells maintenance and function.
To investigate the mechanisms of PROX1 action in CRC, we carried out PROX1 genome location analysis and identified genes regulated by PROX1. As expected, a significant number of direct PROX1 target genes were identified (Table S1) , and we began investigating their individual contribution. Here, we show that a pro-apoptotic member of the BCL2 family, BCL2L15 (Dempsey et al., 2005) , is induced in hypoxic PROX1 À , but not PROX1 + , cancer cells and that BCL2L15 can in part recapitulate the phenotype of PROX1 deficiency, such as increased clonogenic growth of tumor organoids or tumor development in vivo. These results indicate that apoptosis evasion under metabolic stress conditions is important for the prosurvival function of PROX1 + in metastases. Most likely, the role of other potentially interesting targets and their combinatorial interactions will need to be addressed in the future. Of interest, Annexin A1, identified as a PROX1 effector by Wiener et al. (2014) is another direct target of PROX1 in our data set (Table S1 ).
With few exceptions, transcription factors are considered undruggable. To overcome this limitation, we searched for pharmacological approaches to target PROX1 + tumor cells.
We found that inhibition of autophagy, a catabolic process providing an alternative energy source, eliminates the growth advantage of PROX1 + CRC cells and decreases metastatic burden. Of interest, following CQ treatment, viable tumor cells are located in the vicinity of blood vessels and they remain accessible for cytotoxic drugs. Thus, a combination of targeted anti-PROX1 therapy with antiproliferative/cytotoxic 5-fluorouracil-based chemotherapy might be pursued as a potential treatment option for CRC patients with PROX1 + metastatic disease. We propose the following working model of PROX1's role in metastasis: high Wnt signaling induces PROX1 expression in CRC cells and PROX1 + cancer stem/progenitor cells become resistant to metabolic stress, in part through the repression of BCL2L15. Because PROX1 is produced only in CRC, but not normal stem cells, and metabolic stress is high in metastases, these data provide one of the mechanisms of how oncogenic Wnt signaling induces cancer cell adaptation and promotes metastatic cell outgrowth. A related intriguing question is whether increased fitness of PROX1 + tumor cells reflects the role of PROX1 in normal tissues. The highest levels of Prox1 are found in lens fiber cells (Oliver et al., 1993) . The lens is an avascular organ, located in a physiologically hypoxic and glucose-poor environment (Mathias et al., 1997; Trayhurn and Van Heyningen, 1972) , and it is not fully understood how the lens maintains homeostasis in such conditions. Similarly, PROX1 + lymphatic vessels, unlike blood vessels, do not need basement membrane or pericytes to survive, grow in relatively hypoxic environment, and do not regress after removal of proliferative stimuli (Baluk et al., 2005) . Thus, it seems plausible that PROX1 enhances adaptation of normal cells to unfavorable metabolic conditions.
An important observation of this study is the differential role of PROX1 in metastases versus primary tumors in advanced colorectal cancer. In our models, all of which carry mutations in oncogenic and tumor suppressor genes APC, KRAS, and TP53, PROX1 suppression decreased metastasis size and proliferation, whereas having little effect on the size or proliferation of primary tumors. Whereas the mechanisms are yet unknown, we propose that PROX1 is needed to provide a survival advantage to metabolically stressed cells. This is supported by the fact that CQ treatment is more effective in reducing growth of (legend continued on next page) PROX1 + metastasis versus primary tumors and that metastases have higher levels of autophagy. Interestingly, whereas generally PROX1 increases metastases size, PROX1 + and PROX1 À metastases have a comparable size in skeletal muscle ( Figure 3E ). These data indicate that metabolically active tissue such as skeletal muscle can complement the deficiency in PROX1. They also highlight important differences in metabolism of metastases versus primary tumors and further underscore a need to better understand and exploit such differences. Previous studies documented a critical role of stromal inflammation, extracellular matrix, and chemokine/growth factor signaling for the successful outgrowth of cancer cells (Chaffer and Weinberg, 2011; Bhowmick, 2012; Zeelenberg et al., 2003) . Our work reveals a cancer-type-specific mechanism of metastasis progression by demonstrating that the CRC-specific Wnt target gene PROX1 increases metabolic fitness of metastatic cancer stem cells. Importantly, all human and mouse models used in the study carry an activating mutation in KRAS, which underlies intrinsic or acquired resistance to targeted anti-EGFR therapies (Van Emburgh et al., 2014 
Bioinformatics Analyses
The correlation analysis of PROX1 expression with cell differentiation, proliferation, and stem cell markers was based on GSE41258 data set (Sheffer et al., 2009 For western blotting, proteins were resolved by SDS-PAGE, transferred onto Immobilon-P, and detected with horseradish-peroxidase-conjugated secondary antibodies (Dako) and enhanced chemiluminescence (Thermo Fisher Scientific).
PROX1 ChIP-Seq and Reporter Analyses
Pools of three independent ChIP experiments and input DNA were used for sequencing (see Supplemental Experimental Procedures).
ChIP-seq data, generation of BCL2L15 luciferase reporter constructs, and their analyses are described in Supplemental Experimental Procedures.
(G) BCL2L15 limits growth of metastases. GFP-or BCL2L15-expressing SW620 cells were injected i.v., and metastases were analyzed 30 days later. Staining for PROX1 (green), EdU (red), and DNA (blue). The scale bar represents 100 mm. 
Statistical Analyses
We used Prism 5.0 for laboratory data analysis. p value % 0.05 was considered to be statistically significant. Full description of statistical analyses is provided in Supplemental Experimental Procedures.
